IIA-HGSOC

  • Research type

    Research Study

  • Full title

    Integrated Image Analysis in High Grade Serous Ovarian Cancer

  • IRAS ID

    273267

  • Contact name

    Evis Sala

  • Contact email

    es220@cam.ac.uk

  • Sponsor organisation

    Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge

  • Duration of Study in the UK

    4 years, 11 months, 30 days

  • Research summary

    Integrated Image Analysis in High Grade Serous Ovarian Cancer

    High-grade serous ovarian cancer (HGSOC) represents the most lethal gynecologic malignancy and is the fifth leading cause of cancer-related deaths in women. Importantly, the global cancer death rate as a whole has dropped by 23% since 1991, yet death rates for patients with ovarian cancer have remained stagnant over the past two decades. Although patients with HGSOC show initial sensitivity to platinum-based chemotherapy, most recur and become progressively resistant to platinum-based chemotherapy and other subsequent treatments.
    The high tumour heterogeneity of HGSOC is believed to be responsible for this phenomenon. Our team has developed novel ways to assess tumour heterogeneity on computed tomography (CT) images which are routinely performed for staging and response assessment in patients with HGSOC.

    This retrospective study aims to evaluate whether advanced imaging markers such as (whole tumour volume, metric of inter- and intra-side heterogeneity) predict with clinical endpoints (i.e. progression-free survival) and correlate with biological tissue characteristics.

    This retrospective study will analyse CT images of patients with HGSOC treated in 22 trial centres, which were prospectively included in the clinical ICON8 trial. Patient included in this clinical trial had regular CT examination before, during and after treatment. We will analyse anonymised CT images before the start of treatment, before surgery and at time of disease progression and extract imaging markers at each time point.
    Demographic and clinical data will be provided by the ICON8 trial team (MRC).

    The total duration of the study is five years.

  • REC name

    N/A

  • REC reference

    N/A